Translation of "thérapeutique rationnelle du comportement " (French → English) :

– (EL) I should like to refer to the concept of rational expectations and rational behaviour and to say that, obviously, any conclusions within the framework of the negotiations being carried out inside the European Union will not be adopted if there is any prospect that they cannot be safeguarded or they cannot be compatible with what is decided at world level.

1. RECALLS the Council Conclusions on Medicinal Products and Public Health of 29 June 2000 , which stress the need for greater actions in the area of added therapeutic value, rational use of medicines and information to patients;

The rapporteur starts from a correct and appropriate premise and gives a rational presentation of the real causes of Europe’s current recession and provides a logical suggestion for an appropriate remedy.

The rapporteur starts from a correct and appropriate premise and gives a rational presentation of the real causes of Europe’s current recession and provides a logical suggestion for an appropriate remedy.

1. Takes note of the conclusions of the debates at the European Conference on Medicinal Products and Public Health held at Lisbon on 11 and 12 April 2000 on the future of the European System for Evaluation and Supervision of Medicinal Products, the relevance of the added therapeutic value of medicinal products, aspects determining innovation and research, the rational use of medicinal products, the importance and evolution trends for the information systems for medicinal products, the increasing use of generic medicines and the key is ...[+++]sues on veterinary medicinal products.

The key deliverables of the initiative include an assessment of the TPP cost-recovery initiative as it relates to the Treasury Board cost-recovery policy, and the public and private benefits that have derived from it; a thorough assessment of the current cost-recovery initiative costing model used by the TPP, including a comparison of other regulatory regimes and justifications, identification of any gaps in the current cost-recovery initiative, and the contribution of fees to the delivery of an efficient service; an evaluation of whether the cost-recovery initiative has had an impact on the TPP's performance, taking into consideration previous performance commitments, other ju ...[+++]risdictions' experience, options for improving feedback and/or communication mechanisms for stakeholders to foster transparency and accountability, and constraints that might limit my program's ability to manage the cost-recovery initiative and thereby the efficient operations of its programs; an assessment of the direct, indirect, and cumulative impacts of the cost-recovery initiative on therapeutic products industries, on consumers and the health care system, and on the TPP itself, and the development of a rigorous methodology and relevant data sources for a follow-up assessment of the impact of planned fees on the medical devices regulation area; and finally, a systematic review of lessons learned from other jurisdictions and options for operational and/or organizational alternatives and/or modifications to improve the management of the TPP cost recovery initiative.